MARKET

ORPH

ORPH

Orphazyme A/S
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.28
-0.14
-2.58%
Pre Market: 5.34 +0.06 +1.14% 09:16 07/26 EDT
OPEN
5.46
PREV CLOSE
5.42
HIGH
5.52
LOW
5.20
VOLUME
37.54K
TURNOVER
--
52 WEEK HIGH
77.77
52 WEEK LOW
4.750
MARKET CAP
183.01M
P/E (TTM)
-1.4569
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 07/16 16:39
NEGG, BBIG, ORPH among mid-day gainers
Gaiers: TD Holdings (GLG) +45%.GX Acquisition (GXGX) +40%.China SXT Pharmaceuticals (SXTC) +35%.Newegg Commerce (NEGG) +17%.Orphazyme (ORPH) +17%.TDH Holdings (PETZ) +16%.Aehr Test Systems (AEHR) +14%.Byrna Technologies (BYRN) +13%.Jewett-Cameron Trading C...
Seekingalpha · 07/16 16:34
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced the closing of its previously announced sale ...
Business Wire · 07/16 12:00
Thinking about buying stock in Ford, American Airlines, Plug Power, Orphazyme, or Snap?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, AAL, PLUG, ORPH, and SNAP.
PR Newswire - PRF · 07/13 14:30
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has entered into a securities purchas...
Business Wire · 07/13 12:00
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common co...
GlobeNewswire · 07/09 11:25
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 07/02 19:30
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.
Benzinga · 07/01 21:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORPH. Analyze the recent business situations of Orphazyme A/S through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORPH stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 289.46K
% Owned: 0.84%
Shares Outstanding: 34.66M
TypeInstitutionsShares
Increased
0
0
New
4
138.90K
Decreased
4
22.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About ORPH
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Webull offers kinds of Orphazyme A/S stock information, including NASDAQ:ORPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORPH stock methods without spending real money on the virtual paper trading platform.